Harmony Biosciences Holdings, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

· · · · · ·
· · Three Months Ended March 31,
· · 2026 · · 2025
Net product revenue	$215,387	$184,733
Cost of product sold	44,512	31,994
Gross profit	170,875	152,739
Operating expenses:
Research and development	69,383	34,540
Sales and marketing	31,694	30,711
General and administrative	32,507	31,243
Total operating expenses	133,584	96,494
Operating income	37,291	56,245
Other expense, net	(127)	(276)
Interest expense	(3,234)	(3,836)
Interest income	5,757	5,044
Income before income taxes	39,687	57,177
Income tax expense	(7,199)	(11,617)
Net income	$32,488	$45,560
Unrealized (loss) income on investments	(759)	179
Comprehensive income	$31,729	$45,739
EARNINGS PER SHARE:
Basic	$0.56	$0.79
Diluted	$0.55	$0.78
Weighted average number of shares of common stock - basic	57,819,060	57,309,938
Weighted average number of shares of common stock - diluted	58,776,297	58,524,566

UNAUDITED CONDENSED CONSOLIDATED

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.